Leukogene Therapeutics Announces Two Presentations at the AACR Annual Meeting 2026 Highlighting MHC Class II-Engager Immunotherapies

AI Briefing

• – Leukogene Therapeutics to present MHC class II-engager immunotherapies for AML and pancreatic cancer at AACR Annual Meeting 2026.
• – Company's lead development candidates show promising results in immunologically cold cancers.
• – Posters to be presented on November 6-10, 2026, in San Diego, California.